Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Nastech drug delivery, infectious, autoimmune news

NSTK will restructure and spin out its MDRNA Inc. subsidiary to develop RNAi therapeutics, including several compounds that are in

Read the full 205 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE